HUE060471T2 - Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási módszerek - Google Patents

Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási módszerek

Info

Publication number
HUE060471T2
HUE060471T2 HUE21164434A HUE21164434A HUE060471T2 HU E060471 T2 HUE060471 T2 HU E060471T2 HU E21164434 A HUE21164434 A HU E21164434A HU E21164434 A HUE21164434 A HU E21164434A HU E060471 T2 HUE060471 T2 HU E060471T2
Authority
HU
Hungary
Prior art keywords
ultra
methods
fusion proteins
long acting
acting insulin
Prior art date
Application number
HUE21164434A
Other languages
English (en)
Inventor
Thomas Lancaster
Todd Zion
Original Assignee
Akston Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akston Biosciences Corp filed Critical Akston Biosciences Corp
Publication of HUE060471T2 publication Critical patent/HUE060471T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
HUE21164434A 2018-06-29 2019-06-28 Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási módszerek HUE060471T2 (hu)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862692498P 2018-06-29 2018-06-29
US201862692507P 2018-06-29 2018-06-29
US201862693814P 2018-07-03 2018-07-03
US201862696645P 2018-07-11 2018-07-11
US201862698648P 2018-07-16 2018-07-16
US201862702167P 2018-07-23 2018-07-23
US201862719347P 2018-08-17 2018-08-17
US201862740735P 2018-10-03 2018-10-03
US201862743358P 2018-10-09 2018-10-09
US201862774682P 2018-12-03 2018-12-03
US201862781378P 2018-12-18 2018-12-18
US201862781368P 2018-12-18 2018-12-18
US201962824176P 2019-03-26 2019-03-26
US201962827809P 2019-04-01 2019-04-01
US201962837188P 2019-04-22 2019-04-22

Publications (1)

Publication Number Publication Date
HUE060471T2 true HUE060471T2 (hu) 2023-03-28

Family

ID=68985236

Family Applications (4)

Application Number Title Priority Date Filing Date
HUE21207279A HUE062719T2 (hu) 2018-06-29 2019-06-28 Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások
HUE21164434A HUE060471T2 (hu) 2018-06-29 2019-06-28 Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási módszerek
HUE19826154A HUE058005T2 (hu) 2018-06-29 2019-06-28 Ultra hosszan ható inzulin Fc fehérjék, és alkalmazási eljárások
HUE22203969A HUE065725T2 (hu) 2018-06-29 2019-06-28 Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási eljárások

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE21207279A HUE062719T2 (hu) 2018-06-29 2019-06-28 Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE19826154A HUE058005T2 (hu) 2018-06-29 2019-06-28 Ultra hosszan ható inzulin Fc fehérjék, és alkalmazási eljárások
HUE22203969A HUE065725T2 (hu) 2018-06-29 2019-06-28 Ultra-hosszú hatású inzulin-FC fúziós fehérjék és alkalmazási eljárások

Country Status (15)

Country Link
US (8) US10961294B2 (hu)
EP (5) EP3892628B1 (hu)
JP (2) JP7417277B2 (hu)
KR (1) KR20210029210A (hu)
CN (1) CN113038964A (hu)
AU (1) AU2019291945A1 (hu)
BR (1) BR112020026777A2 (hu)
CA (1) CA3104144A1 (hu)
DK (4) DK4011908T5 (hu)
FI (2) FI4186920T3 (hu)
HR (4) HRP20230991T1 (hu)
HU (4) HUE062719T2 (hu)
LT (4) LT3892628T (hu)
SI (4) SI3892628T1 (hu)
WO (1) WO2020006529A1 (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE055417T2 (hu) 2016-12-09 2021-11-29 Akston Biosciences Corp Inzulin-Fc fúziók és alkalmazási eljárások
EP3892628B1 (en) 2018-06-29 2022-09-07 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
WO2021011827A1 (en) * 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
FI4073098T3 (fi) * 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
HRP20230990T1 (hr) 2020-04-10 2023-12-08 Akston Biosciences Corporation Antigen specifična imunoterapija za fuzijske proteine covid-19 i postupci uporabe
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
JP7532638B2 (ja) * 2020-07-24 2024-08-13 チアンスー ジェンサイエンス インコーポレイテッド インスリン－Ｆｃ融合タンパク質及びその応用
AU2021401635A1 (en) * 2020-12-14 2023-06-22 Eli Lilly And Company Methods of treating diabetes
EP4373861A2 (en) 2021-07-23 2024-05-29 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
WO2023064711A2 (en) * 2021-10-14 2023-04-20 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
AR127619A1 (es) 2021-11-15 2024-02-14 Lilly Co Eli FORMULACIONES CONSERVADAS DE FUSIONES DE INSULINA-Fc
WO2023174370A1 (zh) * 2022-03-16 2023-09-21 北京拓界生物医药科技有限公司 人胰岛素类似物、其融合蛋白及医药用途
WO2023247640A1 (en) * 2022-06-23 2023-12-28 Sanofi Single chain insulins and fc conjugates thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030040601A1 (en) 2001-06-08 2003-02-27 Ivan Diers Method for making insulin precursors and insulin analog precursors
US7169894B2 (en) * 2001-11-14 2007-01-30 Mirari Biosciences, Inc. Methods and compositions for reverse translation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20100143479A1 (en) 2008-12-04 2010-06-10 Oakwood Laboratories, Llc Method of making sustained release microparticles
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
CA2754408A1 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
CN101891823B (zh) 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
JP2013535467A (ja) 2010-07-28 2013-09-12 スマートセルズ・インコーポレイテツド 組換えにより発現されたインスリンポリペプチドおよびその使用
EP2598170A4 (en) 2010-07-28 2016-07-06 Smartcells Inc MEDICAMENT-LIGAND CONJUGATES, THEIR SYNTHESIS AND CORRESPONDING INTERMEDIATES
AR087433A1 (es) 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
WO2013074598A1 (en) * 2011-11-18 2013-05-23 Merck Sharp & Dohme Corp. Fc CONTAINING POLYPEPTIDES HAVING INCREASED ANTI-INFLAMMATORY PROPERTIES AND INCREASED FcRN BINDING
KR102041412B1 (ko) 2011-12-30 2019-11-11 한미사이언스 주식회사 면역글로불린 Ｆｃ 단편 유도체
CN103509118B (zh) * 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
US10371158B2 (en) * 2012-08-17 2019-08-06 Dresser-Rand Company System and method for detecting stall or surge in radial compressors
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
EP3616727B1 (en) 2013-02-26 2021-03-31 Hanmi Pharm. Co., Ltd. Insulin analog conjugates and use thereof
EP3194429A4 (en) * 2014-09-18 2018-06-13 Askgene Pharma, Inc. Novel feline erythropoietin receptor agonists
JP6829928B2 (ja) 2014-10-06 2021-02-17 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ 二相性単鎖インスリン類似体
CA2964918A1 (en) 2014-10-20 2016-04-28 Case Western Reserve University Halogenated insulin analogues of enhanced biological potency
WO2016105545A2 (en) 2014-12-24 2016-06-30 Case Western Reserve University Insulin analogues with enhanced stabilized and reduced mitogenicity
CA2974500A1 (en) 2015-01-20 2016-07-28 Case Western Reserve University Insulin analogues with selective signaling properties and reduced mitogenicity
EP3250589A4 (en) * 2015-01-29 2018-06-20 Nexvet Australia Pty Ltd Therapeutic and diagnostic agents
JP2018508504A (ja) 2015-02-17 2018-03-29 ハンミ ファーマシューティカル カンパニー リミテッド 持続型インスリンまたはインスリンアナログ結合体
WO2016164937A2 (en) * 2015-04-10 2016-10-13 Amgen Inc. Interleukin-2 muteins for the expansion of t-regulatory cells
CN107709355B (zh) * 2015-05-04 2021-09-14 阿珀吉尼科斯股份公司 单链cd40受体激动剂蛋白
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
CN107743494B (zh) 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
EP3757119A1 (en) 2015-11-16 2020-12-30 Ubiprotein, Corp. A method for extending half-life of a protein
EP3481413A4 (en) * 2016-07-08 2020-01-08 Askgene Pharma, Inc. FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2017298565B2 (en) 2016-07-22 2021-08-19 The Walter And Eliza Hall Institute Of Medical Research Insulin analogs
BR112019005637A2 (pt) * 2016-09-23 2019-07-30 Hanmi Pharm Ind Co Ltd análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
EP3526246A1 (en) 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
HUE055417T2 (hu) 2016-12-09 2021-11-29 Akston Biosciences Corp Inzulin-Fc fúziók és alkalmazási eljárások
AR111122A1 (es) 2017-03-07 2019-06-05 Univ Case Western Reserve Análogos de insulina de cadena única estabilizados por un cuarto puente disulfuro
US10572594B2 (en) 2017-08-01 2020-02-25 Intuit Inc. Extracting domain-specific actions and entities in natural language commands recognized based on edition and recognition scores
JP2020531002A (ja) 2017-08-15 2020-11-05 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学用ｉｇｇ ｆｃ変異体
WO2019204206A1 (en) 2018-04-16 2019-10-24 Chou Danny Hung Chieh Glucose-responsive insulin
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP3892628B1 (en) 2018-06-29 2022-09-07 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
CA3114395A1 (en) 2018-09-25 2020-04-02 Absci, Llc Protein purification methods
AR116605A1 (es) 2018-10-05 2021-05-26 Novo Nordisk As Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
US20220002373A1 (en) 2018-11-19 2022-01-06 Case Western Reserve University Single-chain insulin analogues with poly-alanine c-domain sub-segments
WO2020236762A2 (en) 2019-05-17 2020-11-26 Case Western Reserve University Variant single-chain insulin analogues
WO2021011827A1 (en) 2019-07-16 2021-01-21 Akston Biosciences Corporation Ultra-long acting insulin-fc fusion proteins and methods of use
TWI844709B (zh) 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
FI4073098T3 (fi) 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use

Also Published As

Publication number Publication date
EP3892628A1 (en) 2021-10-13
HUE065725T2 (hu) 2024-06-28
EP4344738A2 (en) 2024-04-03
HRP20230991T1 (hr) 2023-12-08
US11261229B2 (en) 2022-03-01
HRP20240408T1 (hr) 2024-06-07
EP4186920B1 (en) 2024-01-03
LT3892628T (lt) 2022-12-12
SI4186920T1 (sl) 2024-05-31
US20200231646A1 (en) 2020-07-23
HUE062719T2 (hu) 2023-11-28
US20240101635A1 (en) 2024-03-28
JP2021530210A (ja) 2021-11-11
KR20210029210A (ko) 2021-03-15
EP3655006A4 (en) 2021-01-13
CN113038964A (zh) 2021-06-25
EP3655006A1 (en) 2020-05-27
US10870686B2 (en) 2020-12-22
BR112020026777A2 (pt) 2021-03-30
DK4011908T5 (da) 2024-08-12
US20200157171A1 (en) 2020-05-21
US10851147B2 (en) 2020-12-01
CA3104144A1 (en) 2020-01-02
HRP20220091T1 (hr) 2022-04-15
EP4344738A3 (en) 2024-05-22
US11673934B2 (en) 2023-06-13
LT4186920T (lt) 2024-04-25
US20220009990A1 (en) 2022-01-13
SI4011908T1 (sl) 2023-10-30
HUE058005T2 (hu) 2022-06-28
EP4011908B1 (en) 2023-06-07
DK4186920T3 (da) 2024-03-25
US20220017590A1 (en) 2022-01-20
HRP20221418T1 (hr) 2023-01-06
US10947292B2 (en) 2021-03-16
US20200407413A1 (en) 2020-12-31
AU2019291945A1 (en) 2021-01-14
US11773151B2 (en) 2023-10-03
DK4011908T3 (da) 2023-08-07
JP7510728B2 (ja) 2024-07-04
SI3655006T1 (sl) 2022-04-29
US10961294B2 (en) 2021-03-30
EP4011908A1 (en) 2022-06-15
LT3655006T (lt) 2022-03-10
EP3655006B1 (en) 2021-11-17
DK4186920T5 (da) 2024-07-22
LT4011908T (lt) 2023-09-11
FI4186920T3 (fi) 2024-03-20
US20200157169A1 (en) 2020-05-21
US20200157170A1 (en) 2020-05-21
JP7417277B2 (ja) 2024-01-18
EP3892628B1 (en) 2022-09-07
FI4011908T3 (fi) 2023-08-04
DK3892628T3 (da) 2022-11-14
JP2024045117A (ja) 2024-04-02
SI3892628T1 (sl) 2023-01-31
WO2020006529A1 (en) 2020-01-02
EP4186920A1 (en) 2023-05-31
DK3655006T3 (da) 2022-02-21

Similar Documents

Publication Publication Date Title
LT3655006T (lt) Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
IL288373A (en) flt3l-fc fusion proteins and methods of use
IL279965A (en) Unified structures and methods for their use
IL280102A (en) Fusion protein containing PD1-4-1BBL and methods of using it
LT4073098T (lt) Itin ilgai veikiantys insulino-fc sulieti baltymai ir jų naudojimo būdai
IL267861A (en) PD1-41BBL conjugate protein and methods of using it
EP3455263A4 (en) CD40L-FC FUSION POLYPEPTIDES AND METHODS OF USE THEREOF
IL267862A (en) SIRPalpha-41BBL conjugate protein and methods of using it
EP3706786A4 (en) BIS SPECIFIC FUSION POLYPEPTIDES AND METHOD OF USING THEREOF
IL280103A (en) Fusion protein containing SIRPalpha-4-1BBL and methods of using it
EP3600429A4 (en) IL-37 FUSION PROTEIN AND METHODS FOR THE MANUFACTURE AND USE OF THE SAME
EP3722305A4 (en) HM-3 FUSION PROTEIN AND USES THEREOF
SG11202104912SA (en) Fusion protein and use thereof
ZA202000595B (en) Novel therapeutic enzyme fusion protein and use thereof
EP3387019A4 (en) RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE
EP3999549A4 (en) ANTI-PDL1 AND SIALIDASE ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF
EP3994180A4 (en) SIALIDASE-HER2 ANTIBODY FUSION PROTEINS AND THEIR METHODS OF USE
EP3994179A4 (en) ANTI-CD20 ANTIBODY AND SIALIDASE FUSION PROTEINS AND METHODS OF USE THEREOF
IL268234A (en) Factor ix fusion proteins and methods of making and using same